Free Trial

Andrew S. Analyst Performance

Analyst at HC Wainwright

Andrew S. is a stock analyst at HC Wainwright, covering 13 publicly traded companies across a range of sectors. Over the past year, Andrew S. has issued 14 stock ratings, including buy and hold recommendations. While full access to Andrew S.'s proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Andrew S.'s coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
14 Last 0 Years
Buy Recommendations
92.86% 13 Buy Ratings
Companies Covered
13 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy92.9%13 ratings
Hold7.1%1 ratings
Sell0.0%0 ratings

Out of 14 total stock ratings issued by Andrew S. at HC Wainwright, the majority (92.9%) have been Buy recommendations, followed by 7.1% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
13 companies

Andrew S., an analyst at HC Wainwright, currently covers 13 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
13 companies
100.0%

Andrew S. of HC Wainwright specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
11 companies
84.6%
MED - DRUGS
2 companies
15.4%

Andrew S.'s Ratings History at HC Wainwright

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
9/4/2025Initiated Coverage$7.44$7.44Neutral
MetaVia Inc. stock logo
MTVA
MetaVia
9/4/2025Initiated Coverage$0.67$12.00Buy
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
9/4/2025Initiated Coverage$435.27$500.00Buy
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
9/4/2025Initiated Coverage$17.19$60.00Buy
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
9/4/2025Initiated Coverage$45.62$72.00Buy
89BIO stock logo
ETNB
89BIO
9/4/2025Initiated Coverage$9.24$32.00Buy
Savara Inc. stock logo
SVRA
Savara
9/3/2025Boost Price Target$3.39$8.00Buy
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
9/3/2025Reiterated Rating$7.55$22.00Buy
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
8/15/2025Boost Price Target$46.10$75.00Buy
Savara Inc. stock logo
SVRA
Savara
8/15/2025Upgrade$3.01$5.00Buy
Arvinas, Inc. stock logo
ARVN
Arvinas
8/7/2025Lower Price Target$6.11$18.00Buy
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
8/6/2025Lower Price Target$6.88$25.00Buy
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
8/5/2025Lower Price Target$472.27$478.00Buy
Prothena Corporation plc stock logo
PRTA
Prothena
8/5/2025Reiterated Rating$6.94$14.00Buy